Novartis builds case for MS drug ofatumumab as FDA decision ...

Novartis has reported new data with its multiple sclerosis (MS) drug ofatumumab showing that it can suppress disease activity for up to two years, as it waits for an FDA decisi

Novartis offers reimbursement options as EU backs costly SMA...

Novartis’ AveXis unit has said European regulators have approved its Zolgensma (onasemnogene abeparvovec) gene therapy for the rare childhood wasting disease spinal muscular atrophy (SMA),

Novartis on point in EU for asthma triple as CHMP backs Ener...

FDA hastens development of Novartis' Kymriah in follicular l...

Novartis will receive extra help from the FDA during the development of its CAR-T cancer cell therapy Kymriah for follicular lymphoma, after the regulator deemed it to be an advanced regene

Novartis plans large-scale trial of COVID-19 drug hydroxychl...

Novartis has announced plans to begin a large-scale trial of hydroxychloroquine in patients hospitalised with COVID-19, which could give a definitive answer about whether th

Novartis to speak at SMi Group’s Injectable Drug Delivery 20...

Novartis to speak at Injectable Drug Delivery 2020